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Abstract A novel aspartic proteinase, called napsin, has
recently been found in human and mouse. Due to high similarity
with cathepsin D a structural model of human napsin A could be
built. Based on this model a potential epitope SFYLNRD-
PEEPDGGE has been identified, which was used to immunize
rabbits. The resulting antibody was employed in monitoring the
expression of recombinant human napsin A in HEK293 cell line.
Western blot analysis confirmed the specificity of the antibody
and showed that human napsin A is expressed as a single chain
protein with the molecular weight of approximately 38 kDa.
Immunohistochemical studies revealed high expression levels of
napsin A in human kidney and lung but low expression in spleen.
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1. Introduction
Aspartic proteinases belong to the class of endopeptidases.
They contain two Asp residues in the active site, each in a
distinct domain of the enzyme [1,2]. Other members of this
family of enzymes are cathepsin D and E, renin, pepsin, gas-
tricsin, and bovine chymosin. Many of these enzymes have
been extensively studied because of their well-de¢ned physio-
logical roles and their involvement in pathological states re-
lated to cancer [3] or other diseases [4].
Recently a new aspartic proteinase has been described in
humans and mouse, respectively [5,6]. This new human en-
zyme, called napsin, is found in two isoforms, napsin A and
B, which share high sequence homology (85%). While napsin
A seems to be a functional aspartic proteinase predominantly
expressed in lung and kidney, napsin B is transcribed exclu-
sively in cells associated with the immune system. Tatnell et
al. suggest that napsin B might be a transcribed pseudogene
lacking a stop codon and as a result it is possible that the
protein product is rapidly degraded and, therefore, di⁄cult to
detect [5]. Human aspartic proteinases pepsin and gastricsin
are secreted by the stomach, cathepsin E is found in the en-
doplasmatic reticulum of erythrocytes and stomach mucosa
cells [7], whereas cathepsin D is located in lysosomes of var-
ious cell types. The fact that mRNA of napsin A is speci¢cally
localized in kidney and lung tissue suggests a possible di¡er-
ence in its biological function from other aspartic proteinases.
In situ hybridization of kidney-derived aspartic proteinase
(KAP), a mouse homolog of napsin, resulted in strong signals
in the outer stripe of the outer medulla predominantly local-
ized in the proximal straight tubule [6]. It is of interest
whether human napsin A has a similar tissue localization as
KAP.
The goal of this work was to express human napsin A and
obtain a speci¢c polyclonal antibody which was then em-
ployed in immunochemical studies using Western blots and
in tissue localization studies.
2. Materials and methods
2.1. Modeling
A sequence alignment of napsin A and sequences of aspartic pro-
teinases with known 3D structure revealed highest sequence identity
(49%) with human cathepsin D. The structure of pepstatin-inhibited
human cathepsin D [8] was chosen as template to build a 3D model of
human napsin A using an SGI O2 workstation and our in-house
modeling software Moloc [9]. The correctness of the model was
checked with Moloc and a program by Luthy et al. [10].
2.2. Design and synthesis of a polyclonal antibody
A napsin A-speci¢c polyclonal antibody was produced by immuniz-
ing rabbits with a 15 amino acid long peptide SFYLNRD-
PEEPDGGE. Immunization of rabbits and serum preparation was
performed by Genosys Biotechnology, Cambridgeshire, UK. Serum
was collected after several bleedings and tested for detection of napsin
A (1:1000 dilution) transblotted on nitrocellulose membrane from
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels (Novex, San Diego, CA, USA). For evaluation of puta-
tive cross-reactivity the corresponding napsin B-speci¢c antigenic pep-
tide SFYFNRDPEVADGGE was synthesized.
2.3. DNA construction, cell culture and lysate preparation
The mouse sequence of kidney-derived aspartic proteinase ([5] ; Ac-
cession number: em_ro:mmd8991) was used to search the Incyte TM
database for homologous human EST clones. Two subgroups were
identi¢ed which represented two human isoforms of the mouse pro-
tein. One EST clone harboring the putative translational start codon
was obtained from Incyte and sequencing revealed that the insert
contained the entire coding region for napsin A. This insert was fur-
ther subcloned into pcDNA3.1, an expression vector (Invitrogen
Corp., San Diego, CA, USA) containing a CMV promotor and a
marker for G418 selection.
HEK293 cells were maintained in growth medium MEM++, sup-
plemented with 10% FCS, L-glutamine and penicillin/streptomycin
(Life Technologies Inc., Gaithersburg, MD, USA) in a humidi¢ed
incubator with 5% CO2 at 37‡C. To create stable lines these cells
were transfected with the expression vector containing human napsin
A and carrying the G418 resistance gene using lipofectamine (Life
Technologies) according to the manufacturer’s protocol. After 48 h
the cells were split and grown in growth medium supplemented with
0.5 mg/l of G418 (Sigma, St. Louis, MO, USA). Medium was changed
twice a week and resistant colonies were isolated 16 days after trans-
fection. Lysate from several colonies was prepared by sonication of
the cellular pellet in PBS containing 20 mM EDTA and 1 mM PMSF.
From such lysates a crude pellet fraction was isolated by centrifuga-
tion at 14 000 rpm in an Eppendorf centrifuge cooled to 4‡C. The
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pellet fraction was further eluted in the same bu¡er containing 1%
Elugent (Calbiochem-Novabiochem, La Jolla, CA, USA). After a
second centrifugation step the lysates were split into aliquots and
stored at 4‡C for immediate use or at 380‡C for long term storage.
The total protein concentration was determined and the samples were
analyzed for the appearance of recombinant human napsin A using
Western blot analysis.
2.4. Electrophoresis and Western blot analysis
SDS-PAGE was carried out by following the method of Laemmli
(1970) [11]. In brief, cell homogenate was heated at 95‡C for 5 min in
reducing sample bu¡er and subjected to SDS-PAGE using 4^20%
Tris-glycine gels (Novex). Electrophoresis was performed for 1 h at
a constant 200 V. Proteins were subjected to electroblotting onto a
nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala,
Sweden) for 2 h at 25 V using 25 mM Tris/192 mM glycine/20% (v/
v) methanol as a bu¡er system. See-Blue prestained standards (Novex)
were used as molecular mass standards. The membrane was blocked
using 20% newborn fetal serum in PBS supplemented with 0.1% (v/v)
Tween-20 (PBSt) for 1 h at room temperature, washed with PBSt, and
incubated for 1 h at room temperature with anti-napsin A antibody
(1:1000, v/v). After washing the membrane with PBSt (1U15 min and
2U5 min), the membrane was incubated for 1 h at room temperature
with HRP-conjugated anti-rabbit Ig from donkey (1:5000, v/v)
(Amersham), and the IgG was detected with the enhanced chemilu-
minescence system (Amersham) in accordance with the manufactur-
er’s instructions.
2.5. Immunohistochemical analysis
The cellular localization and the expression pattern of napsin A
were studied by di¡erent immunohistochemical techniques in normal
human kidney, lung and spleen. The human kidney tissue (n = 7) was
either obtained from tumor-remote parts of tumor resections or from
donors without history of medical problems or medications who died
in a motor vehicle accident. Normal lung tissue (n = 3) was also ob-
tained from brain-dead donors, whereas the spleen tissue (n = 2) was
obtained from patients dying from bronchopneumonia. The tissue was
either ¢xed in 4% neutral-bu¡ered formalin or in methyl carnoy’s
¢xative prior to embedding in para⁄n. For the detection of napsin
A on 4 Wm thick para⁄n sections of kidney and lung, we used the
DAKO Envision system (K4010) with peroxidase/diaminobenzidine as
the enzyme/chromogen solution as well as the immunogold silver
staining method (Zymed Histogold Kit 95-6149) which eliminates
the problem of endogenous enzyme activity. When the Envision sys-
tem was applied, the endogenous peroxidase activity was blocked with
3% hydrogen peroxide. Unspeci¢c background staining was blocked
by incubating the sections with goat serum and by additionally pre-
absorbing the primary and the labeled polymer conjugated with the
secondary antibody with human serum (1:2 dilution) overnight at
4‡C. For the immunogold silver staining method, a non-immune se-
rum blocking solution was used to eliminate non-speci¢c protein bind-
ing followed by the anti-napsin A antibody, which was preabsorbed
overnight with human serum at 4‡C. Then an anti-rabbit secondary
antibody, conjugated to 5 nm colloidal gold was added. The gold
signal was intensi¢ed by applying the silver enhancing solution o¡ered
in the kit. The stain was either viewed by transmission light micros-
copy in which a positive signal appeared as a very intense gray to
black signal or by epipolarization using a £uorescent microscope with
an A-Pol ¢lter set (polarizer, neutral beam splitter, analyzer) which
can increase sensitivity by a factor greater than 100. The immunohis-
tochemical detection of napsin A on the spleen tissue was done by
LifeSpan BioSciences (Seattle) using a Vector ABC-alkaline phospha-
tase kit (AK5002) with the Vector Red substrate kit (SK-5100) to
produce a fuchsia-colored red deposit. Counterstaining was performed
using Mayer’s hematoxylin. Negative controls included staining with
the preimmune serum or with non-immune rabbit IgG in the absence
of the napsin antibody.
3. Results and discussion
3.1. Design of anti-napsin A-speci¢c antibody
The amino acid identity of the mature region of napsin A
[5] with other human aspartic proteinases is quite high (40^
50%). Crystal structures of many aspartic proteinases have
been solved and showed rather high similarity in the overall
folding [8,12^14]. Of all proteins with known 3D structure
human cathepsin D has the highest amino acid identity with
napsin A. Therefore, we used the structure of cathepsin D [8]
as template to build a 3D model of napsin A. With the help
of this model we have identi¢ed a peptide, SFYLNRD-
PEEPDGGD (¢rst aspartate in the DPEEPD sequence corre-
sponds to position 158 in pepsin numbering), suitable for the
immunization of rabbits yielding polyclonal antibodies. The
underlined DPEEPD sequence is likely to be located within a
loop. We assume the two glutamates to be involved in favor-
able antigen-antibody interactions while the two £anking pro-
lines are likely to rigidify the loop and, therefore, decrease the
number of loop conformations. A comparison with other as-
partic proteinases revealed that the DPEEPD sequence is only
found in napsin A (Fig. 1). This should provide high antibody
speci¢city for this enzyme compared to other human aspartic
proteinases, including the napsin B isoform.
3.2. Expression of the napsin A gene
In order to generate immunoreactive protein for in vivo
studies, we expressed human napsin A in human embryonic
kidney cells (HEK293) as described in Section 2. The expres-
sion vector contained the full cDNA sequence of napsin A
Fig. 1. Alignment of the peptide sequence used as the antigen to
raise anti-napsin A polyclonal antibody to the equivalent sequences
of napsin B, cathepsin D, renin, cathepsin E, and pepsin. Gaps are
introduced for maximal alignment. Sequences are listed with de-
creasing similarity from top to bottom. Napsin A unique sequence
is underlined. Residues di¡erent to those in human napsin A are
shown in bold.
Fig. 2. Western blot of recombinant human napsin A expressed in
HEK293 cells using anti-napsin A polyclonal antibody raised
against the peptide SFYLNRDPEEPDGGE. See text for details.
Lanes 1 and 2 contain detergent treated pellet fraction of non-trans-
fected HEK293 cells and HEK293 cells expressing recombinant hu-
man napsin A, respectively. The molecular mass standards corre-
sponding to myosin (250 kDa), BSA (98 kDa), glutamic
dehydrogenase (64 kDa), alcohol dehydrogenase (50 kDa), carbonic
anhydrase (36 kDa), myoglobin (30 kDa), and lysozyme (16 kDa)
are shown in lane 3.
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encoding for 420 amino acids. The sequence comprises the
signal peptide, propeptide and the mature enzyme [5].
Immunoreactivity of expressed napsin A was analyzed by
immunochemical detection using anti-napsin A antibody.
Electrophoresis of crude HEK293 cell extract containing nap-
sin A in sodium dodecylsulfate (SDS) polyacrylamide gel fol-
lowed by transblotting of proteins to a nitrocellulose sheet
and immunochemical staining with antibody showed a single
band with the apparent molecular weight of approximately 38
kDa (Fig. 2). This value is close to the calculated molecular
Fig. 3. Immunohistochemical localization of napsin A in human kidney and lung. A: Part of the renal cortex demonstrating intense staining
for napsin A in proximal convoluted tubules (arrows), whereas no signi¢cant staining is found in the glomerulus (detection by immunogold sil-
ver staining, epipolarization). B: Proximal convoluted tubules at higher magni¢cation with clearly visible brush borders (arrows) are strongly
stained with the napsin A antibody (immunogold silver staining, no epipolarization). C: Collecting duct in the medulla shows positive staining
for napsin A along the luminal border (DAKO Envision detection system with peroxidase/DAB). D: Type II pneumocytes (arrow) in the alveo-
lar epithelium show strong staining for napsin A (immunogold silver staining, epipolarization). All sections were counterstained with Mayer’s
hematoxylin.
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weight of tentative mature napsin A (V39 kDa). Since no
other bands were observed, it can be concluded that the poly-
clonal antibody speci¢cally recognizes mature napsin A (the
antibody did not cross-react with human cathepsin D tested
separately, data not shown). However, we can not exclude
that the antibody can recognize pronapsin A as well. Absence
of the second band corresponding to the zymogen (calculated
molecular weightV43 kDa) suggests that napsin A undergoes
maturation. Di¡erent ways of maturation of other eukaryotic
aspartic proteinases have been described in literature
[1,2,15,16]. At present, we can only speculate about a mech-
anism by which pronapsin A matures.
During the expression procedure in HEK293 cells we have
observed by Western blot that not only the cytoplasmic frac-
tion of the cellular lysate but also the remaining cellular pellet
contained a band corresponding to napsin A. Moreover, the
majority of napsin A seemed to be associated with the pellet.
Therefore, in order to release the enzyme into the solution, the
cellular pellet was treated with a PBS bu¡er containing 20 mM
EDTA, 1 mM PMSF and 1% Elugent. This detergent treat-
ment resulted in a very e⁄cient extraction of napsin A into
the bu¡er as con¢rmed by Western blot. Implication of this
observation is that napsin A might be present in large cellular
vacuoles or membrane associated or that the overexpression
in HEK293 cells triggers a mechanism which alters the expres-
sion pathway of recombinant napsin A compared to the na-
tive one. These assumptions are currently under investigation
in our laboratory. It should be pointed out that most of the
human aspartic proteinases described so far are not mem-
brane bound. Notable exceptions are the recently described
human aspartic proteinases ASP1 and ASP2 (patent number
EP848062-A2 and EP855444-A2, respectively), which contain
a transmembrane domain at the C-terminus. On the other
hand, several aspartic proteinases such as Yapsin 1 and Yap-
sin 2 from Saccharomyces cerevisiae [17,18], and the parasites
Eimeria tenella [19] and Plasmodium falciparum [20] have been
described as being membrane anchored. Yeast and E. tenella
enzymes have long C-terminal tails, which are known to be
involved in a glycophosphatidylinositol (GPI) anchoring of
these enzymes. Plasmepsins I and II from P. falciparum are
type II integral membrane proteins, which have a transmem-
brane domain at the N-terminus of the zymogen [20]. Com-
pared to other human aspartic proteinases, napsin A has a
unique C-terminal extension of 18 amino acids [5]. However,
this extension does not contain a transmembrane motive nor
can it be involved in GPI anchoring [5]. Therefore, we assume
membrane association of human napsin A through the C-ter-
minal tail to be highly unlikely. On the other hand, napsin A
contains an RGD motif (position 315 in pepsin numbering),
which can be involved in integrin binding. Therefore, this type
of interaction could potentially be responsible for observed
membrane association of napsin A. However, based on our
computer model it is not apparent that RGD is in a position
to optimally bind to integrin.
3.3. Immunohistochemical studies
Since immunochemical studies con¢rmed the speci¢city of
the anti-napsin A polyclonal antibody, further studies have
been undertaken in order to determine localization of napsin
A in human tissue. It was of interest to elucidate whether the
napsin A gene is translated into protein and, if so, in which
organs this protein is localized. Tatnell et al. reported expres-
sion of the human napsin A gene using Northern blot in
normal kidney and lung [5]. We therefore performed immu-
nohistochemical studies on human kidney and lung sections
by using anti-napsin A antibody.
The samples of normal human kidney showed prominent
staining for napsin A in the cortex region as well as in the
outer stripe of the medulla. The staining within the renal
cortex was predominantly con¢ned to the epithelial cells of
the proximal convoluted and straight tubules as well as the
distal convoluted tubules (Fig. 3A, B). The observed staining
appeared scattered. The glomeruli, including parietal and vis-
ceral podocytes, endothelium of glomerular capillaries, and
mesangial cells were negative for staining. Within the renal
medulla, occasional collecting ducts and the thin loops of
Henle showed faint cytoplasmic staining, but the signal was
also found localized along the luminal border of the cell mem-
brane (Fig. 3C). These ¢ndings are in good accordance with
the results of in situ hybridization of mouse KAP mRNA
expression in the mouse kidney [6]. Mori et al. reported abun-
dant expression of mouse KAP in the proximal straight tubule
and weak, but signi¢cant expression in the proximal convo-
luted tubule. However, as described above, we have also
found expression of napsin A in the distal convoluted tubule,
collecting duct, and Henley loops of human kidney. Whether
this slight variability in the intra-renal distribution between
mouse KAP and human napsin A is due to species di¡erences
requires further investigation. In view of the observed staining
along the luminal border of the cell membrane in collecting
duct and disperse staining within the renal cortex, it would
appear that napsin A is membrane anchored. At present the
mechanism of membrane association of napsin A is unknown.
The samples of normal adult lung showed positive staining
within Type II pneumocytes (Fig. 3D), alveolar macrophages,
and a subset of Type I pneumocytes. Positive staining was
also observed in respiratory epithelium of the terminal and
respiratory bronchioles, plasma cells, and within a subset of
lymphocytes. The majority of ¢broblasts and smooth muscle
cells appeared negative for staining.
We have also performed immunohistochemical study using
human spleen tissue. Staining of the spleen was very limited
Fig. 4. Occasional lymphocytes (arrows) in the periarterial lymphatic
sheat are positively stained with the anti-napsin A antibody (Vector
ABC-alkaline phosphatase detection with Vector Red as chromo-
gen).
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and less intense compared to kidney and lung. However, pos-
itive staining was seen within the sinusoidal endothelial cells
of the cords of Billroth, within the endothelial cells of the
branches of the central artery, and within subsets of lympho-
cytes in the periarterial lymphatic sheaths (Fig. 4). Obtained
data are not in accordance with the results of Tatnell et al. [5]
who reported that only the mRNA encoding napsin B was
present in spleen. One possible explanation for this contra-
diction could be the cross-reactivity of anti-napsin A antibody
with napsin B. In order to address this problem napsin B-
speci¢c antigenic peptide (see Fig. 1) was immobilized onto
the membrane and immunochemical analysis using anti-nap-
sin A antibody was performed. This analysis revealed that the
antiserum does not recognize napsin B antigenic peptide (data
not shown). Peptide used to raise anti-napsin A antibody was
employed as a positive control. These data suggest that the
staining observed in spleen is due to the interaction between
the antiserum and napsin A but not napsin B. However, only
immunochemical study using native or recombinant napsin B
as antigen can clearly rule out the possible cross-reactivity.
Finally, reported absence of an in-frame stop codon of the
napsin B gene [5] does not favor the presence of the napsin B
gene product in the spleen, thus making the cross-reactivity
unlikely. To explain the appearance of immunoreactive napsin
A in the spleen without ¢nding corresponding mRNA further
studies are required.
In summary, we have been able to express recombinant
human napsin A and to obtain a napsin A-speci¢c polyclonal
antibody by taking advantage of the computer modeling ap-
proach. This antibody was useful for immunochemical detec-
tion of human napsin A and immunohistochemical studies of
several human tissues. Results of this study clearly demon-
strate localization of human napsin A in kidney and lung.
We hope that future studies will elucidate the subcellular lo-
calization of napsin A and that these ¢ndings, together with
the immunohistochemical results presented here, can be useful
in investigating the function of this enzyme.
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